The Intracellular Threonine of Amyloid Precursor Protein That Is Essential for Docking of Pin1 Is Dispensable for Developmental Function

Alessia P. M. Barbagallo1,*, Zilai Wang2,*, Hui Zheng2, Luciano D’Adamio1,3*

1 Department of Microbiology and Immunology, Einstein College of Medicine, Bronx, New York, United States of America, 2 Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, United States of America, 3 Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy

Abstract

Background: Processing of Aβ-precursor protein (APP) plays an important role in Alzheimer’s Disease (AD) pathogenesis. Thr residue at amino acid 668 of the APP intracellular domain (AID) is highly conserved. When phosphorylated, this residue generates a binding site for Pin1. The interaction of APP with Pin1 has been involved in AD pathogenesis.

Methodology/Principal Findings: To dissect the functions of this sequence in vivo, we created an APP knock-in allele, in which Thr668 is replaced by an Ala (T668A). Doubly deficient APP/APP-like protein 2 (APLP2) mice present postnatal lethality and neuromuscular synapse defects. Previous work has shown that the APP intracellular domain is necessary for preventing early lethality and neuromuscular junctions (NMJ) defects. Crossing the T668A allele into the APLP2 knockout background showed that mutation of Thr668 does not cause a defective phenotype. Notably, the T668A mutant APP is able to bind Mint1.

Conclusions/Significance: Our results argue against an important role of the Thr668 residue in the essential function of APP in developmental regulation. Furthermore, they indicate that phosphorylation at this residue is not functionally involved in those APP-mediated functions that prevent (NMJ) defects and early lethality in APLP2 null mice.

Introduction

Amyloid-β-precursor protein (APP) plays an important role in Alzheimer’s Disease (AD) pathogenesis [1,2,3,4,5,6,7,8,9,10]. The prevalent Amyloid cascade hypothesis of AD pathogenesis posits that dementia is caused by Aβ aggregates. The repeated failure of therapeutic approaches based on this dogma in humans suggests that alterations of normal APP functions may contribute to AD pathogenesis. Thus, understanding the role of APP in vivo is much needed to reveal fundamental insights into AD pathogenesis and develop potential therapeutic intervention.

APP null mice have given scant information about the functions of APP and these mice exhibit seizures, impaired grip strength, locomotor activity, exploratory activity, cognition and LTP [11,12,13,14,15,16,17,18,19,20,21,22,23,24]. APP Like Protein 1 and 2 (APLP1 and APLP2), which belong to the APP gene family, are structurally [25,26] and functionally similar to APP. The evidence that APLP1−/−, APLP2−/−, APP−/− and APLP1−/−APP−/− mice are viable, whereas combined APP−/−APLP2−/− or APLP1−/−APLP2−/− double KO [27,28] die shortly after birth show that functional redundancy compensates for the loss of essential gene functions in APP knock out mice. Analysis of APP/APLP2 double knockout (dKO) mice uncovered an essential role for the APP and APLP2 in the patterning of neuromuscular junction (NMJ) [29,30,31].

Recent evidence shows that the synaptogenic function of APP requires the highly preserved intracellular domain [32], and in particular Tyr662[33]. This residue is part of the YENPTY sequence (amino acids 682–687, following the numbering of 695 amino acids long brain APP isoform), which is a docking site for numerous cytosolic proteins [34,35,36,37,38,39,40,41,42,43]. Some proteins, such as Grb2 [44,45], S6k [45,46], Grb7 and Crk [47] interact with APP only when Tyr662 is phosphorylated; others, like Fe65, Fe65L1 and Fe65L2 only when this tyrosine is not phosphorylated [48].

Thr668 is another conserved residue of the intracellular region of APP. This residue has been intensively studied as phosphorylation of Thr668 promotes Pin1 binding [49]. The interaction of Pin1 with APP has been shown to reduce APP processing and Aβ generation, thereby protecting from AD [50]. These data are not easily reconcilable with other evidence showing that mutation of Thr668 in vivo does not grossly alter APP processing [51,52]. Here, we asked whether Thr668 and its phosphorylation plays an important physiological role. The NMJ deficits and the early...
postnatal lethality present in the APP/APLP2 double knockout animals provide genetic readouts to determine the role of this amino acid in vivo. We have created an APP knock-in (ki) mouse in which Thr668 is replaced by an alanine (we will refer to these mice as APPTA), thereby abolishing phosphorylation at this position. We report that APPTA/APLP2−/− mice, unlike APP/APLP2 double KO mice, do not present NMJ deficits and early lethality, demonstrating that phosphorylation of Thr668 is dispensable for the essential function of APP in developmental regulation.

**Materials and Methods**

**Mice and Ethics Statement**

Mice were maintained on a C57BL/6 background for several generations (at least 15). Mice were handled according to the Ethical Guidelines for Treatment of Laboratory Animals of Albert Einstein College of Medicine. The procedures were described and approved by the Institutional Animal Care and Use Committee (IACUC) at the Albert Einstein College of Medicine in animal protocol number 20040707. APP-ki generation and genotyping has been described [51]. Genotyping for the APP and APLP2 KO alleles were performed as described in the Jackson Laboratory WEB site.

**Mouse brain preparations and GST pull-down experiments**

Brains were homogenized (w/v = 10 mg tissue/100 ml buffer) in tissue homogenization buffer (20 mM Tris-base pH 7.4, 1 mM EDTA, 1 mM EGTA) supplemented with protease and phosphatase inhibitors (PI and PhI). The post nuclear supernatant (PNS) was prepared by precipitating the nuclei and debris by centrifuging the homogenates at 1000 g for 10 min. GST fusion proteins were produced and purified as described [38]. The binding experiments were performed using ~6 μg (200 pmol) of GST or GST-Mint1 PTB [47] following the methods described previously [38]. To detect the bound APP we used the 22C11 (Chemicon) antibody in Western blot analysis.

**Immunofluorescence staining**

The muscle dissection, preparation, staining, and quantification of the neuromuscular synapses have been previously described [29,31]. Confocal images were obtained with a Zeiss 510 laser-scanning microscope, and quantification was done using the ImageJ program from NIH. Antibodies: anti-synaptophysin (Dako, 1:500); Anti-neurofilament (DSHB 1:500); anti-APP (Epitomics Inc., Y188, 1:250); anti-Alexa-488/555/647 conjugated secondaries and α-bungarotoxin (Molecular Probe).

**Statistical Analysis**

Genotyping analysis of the offspring from APPki/2 APLP2+/- male and female intercrosses was performed using χ² analysis. The Student’s t test was used for all other analyses (*P<0.05; **P<0.01; ***P<0.001). Data were presented as the average ± SEM.

![Figure 1. Survival analysis of APPTA ki mice on APLP2 null background.](image)

Analysis of genotypes of 128 offspring collected at P1 derived from crosses of APPTA/− APLP2+− male and female mice. All genotypes were recovered at close to a Mendelian ratio (df = 8, p>0.95). Analysis of genotypes of these same offspring at P28 showed that the number of APP−/− APLP2−/− animals observed was much lower than expected (highlighted in bold, df = 8, p<0.001). On the contrary, the number of APPTA/TA APLP2−/−, APPTA/− APLP2−/− was still close to a Mendelian ratio (B, df = 8, p>0.20). doi:10.1371/journal.pone.0018006.g001
Expression of APPTA on APLP2 null background does not lead to early postnatal lethality

We tested whether APLP2 KO mice carrying the APPTA mutation have a lethal phenotype, similar to the APP/APLP2 dKO mice. This genetic approach is ideal to assess whether the Thr668 mediates the essential functions of APP. We inter-crossed double heterozygous mice harboring one allele each of the APP and APLP2 null mutations (APPTA/TA and APLP2/TA). We then determined the genotypes of the offspring at postnatal day 1 (P1) and day 28 (P28), and compared the number observed against the number expected (Figure 1A and B).

Genotyping of P1 pups revealed a close to Mendelian distribution of all genotypes, indicating no embryonic lethality as expected (Chi square analysis: at P1, \( \sum d^2/e = 1.775, df = 8, p > 0.05 \)). The distribution of APPTA/TA and APLP2/TA mice did not change between age P1 and P28 (Chi square analysis at P28, \( \sum d^2/e = 10.575, df = 8, p > 0.20 \)) (Figure 1). These results demonstrate that mutation of Thr668 into an Ala does not affect the essential functions of APP that, when compromised, lead to postnatal lethality of the APP/APLP2 double deficient mice. This is in sharp contrast with what is observed in mice with deletion of the entire APP intracellular domain or a point mutation of Tyr682, another conserved residues in the AID, which show early lethality similarly to APP/+/APLP2/−/− animals [32,33].

Analysis of neuromuscular synapses development in APPTA knock-in animals

APPTA/TA and APLP2/TA mice show dramatic defects in the development of NMJ [29,31]. This phenotype, just like the postnatal early lethality, requires the APP intracellular domain and Tyr682 [32,33]. Analysis of the neuromuscular synapse at P0 stage showed that APPTA/TA and APLP2/TA mutants exhibited normal neuromuscular synapses, compared to littermate controls (Figs. 2A and 2C and quantified in 2B and 2D). These results demonstrate that, in agreement with the survival result, Thr668 is not involved in the NMJ analysis of APPTA/TA and APLP2/TA double deficient mice. This is in sharp contrast with what is observed in mice with deletion of the entire APP intracellular domain or a point mutation of Tyr682.

The TA mutation does not affect the APP/Mint1 interaction

It has been proposed that presynaptic differentiation induced by APP involves intracellular association with Cask and Mint1 [31].

Results and Discussion

Expression of APPTA on APLP2 null background does not lead to early postnatal lethality

We tested whether APLP2 KO mice carrying the APPTA mutation have a lethal phenotype, similar to the APP/APLP2 dKO mice. This genetic approach is ideal to assess whether the Thr668 mediates the essential functions of APP. We inter-crossed double heterozygous mice harboring one allele each of the APP and APLP2 null mutations (APPTA/TA and APLP2/TA). We then determined the genotypes of the offspring at postnatal day 1 (P1) and day 28 (P28), and compared the number observed against the number expected (Figure 1A and B).

Genotyping of P1 pups revealed a close to Mendelian distribution of all genotypes, indicating no embryonic lethality as expected (Chi square analysis: at P1, \( \sum d^2/e = 1.775, df = 8, p > 0.05 \)). The distribution of APPTA/TA and APLP2/TA mice did not change between age P1 and P28 (Chi square analysis at P28, \( \sum d^2/e = 10.575, df = 8, p > 0.20 \)) (Figure 1). These results demonstrate that mutation of Thr668 into an Ala does not affect the essential functions of APP that, when compromised, lead to postnatal lethality of the APP/APLP2 double deficient mice. This is in sharp contrast with what is observed in mice with deletion of the entire APP intracellular domain or a point mutation of Tyr682, another conserved residues in the AID, which show early lethality similarly to APP/−/−APLP2/−/− animals [32,33].

Analysis of neuromuscular synapses development in APPTA knock-in animals

APPTA/TA and APLP2/TA mice show dramatic defects in the development of NMJ [29,31]. This phenotype, just like the postnatal early lethality, requires the APP intracellular domain and Tyr682 [32,33]. Analysis of the neuromuscular synapse at P0 stage showed that APPTA/TA and APLP2/TA mutants exhibited normal neuromuscular synapses, compared to littermate controls (Figs. 2A and 2C and quantified in 2B and 2D). These results demonstrate that, in agreement with the survival result, Thr668 is not involved in the NMJ analysis of APPTA/TA and APLP2/TA double deficient mice. This is in sharp contrast with what is observed in mice with deletion of the entire APP intracellular domain or a point mutation of Tyr682.

The TA mutation does not affect the APP/Mint1 interaction

It has been proposed that presynaptic differentiation induced by APP involves intracellular association with Cask and Mint1 [31],

Figure 2. No obvious neuromuscular synapse defects were observed in APPTA/TA and APLP2/−/− mice. A. Whole-mount staining of littermate APPTA/TA and APLP2/−/− control (Ctrl) and APPTA/TA and APLP2/−/− (TA) P0 diaphragm muscles with antibodies against synaptophysin (Syn). Anti-BTX was used to mark the AchRs. B. Quantification of the average band width of endplates marked by anti-BTX (band width in control 260.0±25.17 µm vs. TA 282.9±18.63 µm, p>0.05, student t-test. Mean ± SEM of 3 animals/genotype). C. Higher magnification images showing endplates closely apposed by Syn and no axonal Syn staining in the TA mutant. D. Quantification of the area percentage of AchR endplates covered by Syn (control 0.626±0.024 vs. TA 0.588±0.017. p>0.05, student t-test. Mean ± SEM of 20 endplates/genotype). Scale bar: A, 100 µm; C, 20 µm. doi:10.1371/journal.pone.0018006.g002

Phospho-Thr668 Is Not Required for APP Functions

PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18006
similarly to neurorexin/neuroligin (NX/NL) and SynCAM class of synaptic adhesion proteins [53,54,55]. We asked whether mutation of Thr668 interfered with the formation of a Mint1/APP complex. To test for this, we produced a recombinant protein in vitro, in which the PTB domain of Mint1 was fused to GST for production and purification from bacterial cultures. As a control we produced GST on its own [47]. These recombinant proteins were used for pull down experiments from mouse brain lysates. GST-Mint1 interacts with APP in samples isolated from both WT mice and mice expressing the APPTA mutant form. The interaction is specific since GST does not bring down APP and a molecule reacting with the anti-APP antibody is not isolated by GST-Mint1 pull-down when brain lysates from APP KO mice are used (Fig. 3). These results support the view that the Thr668 mutation does not abolish presynaptic functions of APP because it does not impair the recruitment of Mint1.

The highly conserved APP intracellular region is required for APP-mediated survival and neuromuscular synapse assembly in vivo, and Tyr682 is necessary for these functions of APP [32,33]. We report here that, in contrast, mutant APP mice with a non-phosphorylatable alanyl residue at position 668, have preserved essential APP functions. The non-consequential effects of the mutation on Thr668 suggest that the APP/Pin1 interaction does not impair the recruitment of Mint1.

Thr668 is followed by a Pro, which generates a consensus site for phosphorylation, in APP family members and in other species, except for APLP1 and Drosophila APP orthologue. Phosphorylation of APP at Thr668 impairs F65 interaction [47,36] while promotes Pin1 binding [49]. Pin1 is a prolly isomerase that regulates protein function by accelerating conformational changes. It has been reported that Pin1 is downregulated and/or inhibited by oxidation in Alzheimer's disease neurons [57]. Moreover, pin1 knockout causes tauopathy and neurodegeneration [58], and increased amyloidogenic APP processing [59]. These findings have led to propose that phosphorylation of Thr668 protects from AD by promoting interaction with Pin1, which in turn has a protective effect against amyloidosis and tauopathy. These conclusions however seem to be contradicted by evidence showing that APPTA knock-in mice, in which phosphorylation at position 668 is suppressed, show levels of Aβ comparable to wild type mice, suggest that Thr668 phosphorylation does not play an obvious role in governing the physiological levels of brain Aβ in vivo [51,52].

The evolutionary pressure that has resulted in conservation of this residue during evolution of APP denotes the importance of Thr668 for APP functions. However, the finding that the APPTA mutation rescues NMJ and lethality of APP/APLP2 deficient mice, argues against an essential function for phosphorylation of this residue. The synaptic promoting property of APP may involve the formation of the APP/Mint1/Cask complex in pre-synaptic termini [31]. Mint1 belongs to a gene family that comprises also Mint3. Both Mint1 and 3 bind APP and have opposite effects on the localization of AID [59]. Here we focused on Mint1 because only Mint1 interacts with CASK. In the trans-synaptic interaction model we have previously proposed for APP function in synaptogenesis, APP-Mint1-CASK is likely the central complex mediating APP effect [31]. As discussed, Mint1-CASK complex has also been implicated in Neurorexin-Neuroligin mediated signaling in presynaptic organization [53,54,55]. The finding that Mint1 binds both WT and APPTA mutant but not APPYD [51] backs this hypothesis.

Growing evidence supports a role for alteration of synaptic function in AD. Our previous finding that the intracellular region and Tyr682 of APP plays a role in synaptogenesis makes it a legitimate possibility that the APP intracellular domain may contribute to AD pathogenesis [32,51]. If phosphorylation of Thr668 has a protective role in AD pathogenesis, the finding that APP/ALPL2Δ/Δ mice do not present NMJ development defects represents a notable exception to this hypothesis. However, it is still possible that Thr668 and its phosphorylation may functionally regulate synapses in the Central nervous system, especially those involved in memory formation in the hippocampus. To answer these questions, it will be important to unveil the biological mechanisms that regulate phosphorylation of APP on Thr668 and the signaling pathways that are controlled by this functional domain of APP. In addition, Thr668 and its phosphorylation may regulate signaling pathway that are distinct by those that when compromised double mutant mice, lead to early lethality and NMJ dysfunctions. It is also conceivable that those roles of Thr668 may play a pathogenic role in AD.

Acknowledgments

We thank Erhan Ma for help in the genotyping and PCR procedures on the APP ki mice.

Author Contributions

Conceived and designed the experiments: LD. Performed the experiments: APB ZW HZ LD. Analyzed the data: APB ZW HZ LD. Contributed reagents/materials/analysis tools: APB ZW HZ LD. Wrote the paper: LD ZW HZ.

References

1. De Strooper B (2003) Aplp-1, Prn-2, and Nicastrin with Presenilin generate an active gamma-Secretryase complex. Neuron 38: 9–12.
2. Eder WP, Wolfe MS (2001) A portrait of Alzheimer secretases—new features and familiar faces. Science 293: 1449–1454.
3. Haas C, De Strooper B (1999) The presenilins in Alzheimer's disease—proteolysis holds the key. Science 286: 916–919.
4. Haas C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101–112.
5. Hardy J (2006) Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3: 71–73.
6. Price DL, Wong PC, Markowska AL, Lee MK, Thinakaran G, et al. (2000) The amyloid precursor protein presenilins and Parkinson's diseases. Nat Cell Biol 6: 1054–1061.
3.4 King GD, Scott Turner R (2004) Adaptor protein interactions: modulators of
amyloid beta precursor protein signaling. J Biol Chem 279: 753–765.

3.5 Pietsch CU, Yoon IS, Jaeger S, Busse T, Weggen S, et al. (2004) FE65
constitutes the functional link between the low-density lipoprotein receptor-
related protein and the amyloid precursor protein. J Neurosci 24: 4259–4265.

3.6 Scheinfeld MH, Ghersi E, Davies P, D’Adamo L (2003) Amyloid beta protein
precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-
interacting protein (JIP)-1. J Biol Chem 278: 42038–42043.

3.7 Inomata H, Nakamura Y, Hayakawa A, Takata H, Suzuki T, et al. (2003) A
scaffolding JIP-1 enhances amyloid precursor protein phosphorylation by
JNK and its association with kinase light chain 1. J Biol Chem 278: 29956–29965.

3.8 Matsuda S, Matsuda Y, D’Adamo L (2003) Amyloid beta protein precursor
(ABetaPP), but not ABetaPP-like protein 2, is bridged to the kinase light chain by
the scaffolding JIP-1 interacting protein JNP. J Cell Biol 161: 615–625.

3.9 Muresan Z, Muresan V (2005) Coordinated transport of phosphorylated
amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting
protein-1. J Cell Biol 171: 615–625.

3.10 Fiore F, Zambraños N, Minopoli G, Donini V, Diulio A, et al. (1995) The
regions of the F65 protein homologous to the phosphotyrosine interaction/phospho-
tyrosine binding domain of SH2 bind the intracellular domain of the Alzheimer’s
amyloid precursor protein. J Biol Chem 270: 30853–30856.

3.11 Kimura A, Honokoshi M (1998) Tat66 acetylates six lysines of a specific class
in core histones in vitro. Genes Cells 3: 789–800.

3.12 Scheinfeld MH, Matsuda S, D’Adamo L (2003) JNK-interacting protein-1
promotes transactivation of A beta protein precursor but not A beta precursor-like
proteins, mechanically different than Fe65. Proc Natl Acad Sci U S A 100:
17294–1734.

3.13 Roncarati R, Sestan N, Scheinfeld MH, Berechid BE, Lopeza P, et al. (2002)
The gamma-secretase-generated intracellular domain of beta-amyloid precursor
protein binds Numb and inhibits Notch signaling. Proc Natl Acad Sci U S A 99:
21401–21406.

3.14 Zhou D, Noviello C, D’Ambrosio C, Scaloni A, D’Adamo L (2004) Growth
factor receptor-bound protein 2 interaction with the tyrosine-phosphorylated tail
of amyloid beta precursor protein is mediated by its Src homology 2 domain.
J Biol Chem 279: 23574–23580.

3.15 Russo G, Dolcinia V, Salini V, Venzia V, Zambrano N, et al. (2002) Signal
transduction through tyrosine-phosphorylated C-terminal fragments of amyloid
precursor protein via an enhanced interaction with Src/Grb2 adapter proteins
in reactive astrocytes of Alzheimer’s disease brain. J Biol Chem 277:
35292–35296.

3.16 Tahre PE, Roncarati R, Pellici G, Pellici PG, D’Adamo L (2002) Tyrosine
phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes
interaction with Src. J Biol Chem 277: 16798–16804.

3.17 Tamayev R, Zhou D, D’Adamo L (2009) The interactome of the Amyloid
betaeta Precursor protein family members is shaped by phosphorylation of their
intracellular domains. Mol Neurodegener 4: 21.

3.18 Zhou D, Zambrano N, Russo T, D’Adamo L (2009) Phosphorylation of a
tyrosine in the amyloid-beta protein precursor intracellular domain inhibits Fe65
binding and signaling. J Neurochem 109: 301–307.

3.19 Balastik M, Lim J, Pastorio I, Lu KP (2007) Phn1 in Alzheimer’s disease:
multiple substrates, one regulatory mechanism? Biochim Biophys Acta 1772:
422–429.

3.20 Pastorio I, Lu A, Lu JW, Zhou ZX, Balastik M, et al. (2006) The prolyl
isomerase Phn1 regulates amyloid precursor protein processing and amyloid-
ization production. Nature 440: 528–534.

3.21 Barbagallo AP, Weldon R, Tamayev R, Zhou D, Gilbertho L, et al. (2010)
Tyrosin2 in the Intracellular Domain of APP Regulates Amyloidogenic APP
Processing In Vivo. PLoS One 5: e15503.

3.22 Sano Y, Nakaya T, Pedrini S, Takeda S, Iijima-Ando K, et al. (2006)
Physiological mouse brain Abeta levels are not related to the phosphorylation state of
threonine-668 of Alzheimer’s APP. PLoS ONE 1: e1.

3.23 Biederer T, Sudhof TC (2000) Mints as adaptors. Direct binding to neurones
and recruitment of munc18. J Biol Chem 275: 1729–1734.

3.24 Biederer T, Sudhof TC (1996) CASK: a novel dlg/PSD95 homolog with an
adaptor protein function found in familial Alzheimer’s disease. J Neurosci 32:
469–480.

3.25 Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, et al. (1999)
Neurite extension is caused by a mutation in amyloid beta/A4 (A beta) protein
deficient mice. J Neurosci 27: 4531–4541.

3.26 Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, et al. (2007) The
secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient
to rescue the anatomical, behavioral, and electrophysiological abnormalities of
APP-deficient mice. J Neurosci 27: 7017–7026.

3.27 Li HL, Roch JM, Sundsmo M, Otero D, Sisodia S, et al. (1997) Defective
neurite outgrowth is caused by a mutation in amyloid beta/A4 (A beta) protein
precursor found in familial Alzheimer’s disease. J Neurosci 32: 469–480.

3.28 von Koch CS, Zheng H, Chen H, Trumbauer M, Thimakaran G, et al. (1997)
Generation of aPLP2 KO mice and early postnatal lethality in aPLP2/APP
double KO mice. Neurobiol Aging 18: 661–669.

3.29 Heber S, Herms J, Gajjar V, Hainfellner J, Aguzzi A, et al. (2000) Mice with
combined gene knockouts reveal essential and partially redundant functions of
amyloid precursor protein family members. J Neurosci 20: 7951–7963.

3.30 Wang P, Yang Z, Mosier DR, Chang P, Zaidi T, et al. (2005) Defective
neurotrophin synapses in lacking amyloid beta protein (APP) and APP-Like protein
(KL) mice. J Neurosci 25: 1219–1225.

3.31 Wang P, Yang Z, Wang L, Guo Q, Aihmiti N, et al. (2009) Presynaptic and
postsynaptic interaction of the amyloid precursor protein promotes peripheral
and central synaptogenesis. J Neurosci 29: 10768–10801.

3.32 Li H, Wang Z, Wang B, Guo Q, Dolios G, et al. (2010) Genetic dissection of
the amyloid precursor protein in developmental function and amyloidogenesis.
J Biol Chem 285: 30589–30605.

3.33 Barbagallo AP, Wang Z, Zheng H, D’Adamo L (2011) A single tyrosine residue
in the amyloid precursor protein intracellular domain is essential for
developmental function. J Biol Chem.

3.34 King GD, Scott Turner R (2004) Adaptor protein interactions: modulators of
amyloid precursor protein metabolism and Alzheimer’s disease risk? Exp Neurol
185: 200–219.